Effectiveness and role of zanamivir in the treatment of influenza infection

Annals of Medicine

Volumn 31, Issue 5, 1999, Pages 313-317

  Silagy, Chris A ^b,c   Campion, Katrina ^a  

^a GLAXOSMITHKLINE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

Clinical trials; Influenza; Relenza; Treatment; Zanamivir

Indexed keywords

ANTIVIRUS AGENT; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; BRONCHITIS; CLINICAL TRIAL; COUGHING; DAILY LIFE ACTIVITY; DIARRHEA; DRUG EFFICACY; EAR NOSE THROAT DISEASE; ENZYME INHIBITION; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; NAUSEA; PRIORITY JOURNAL; SHORT SURVEY; VOMITING;

EID: 0032704565     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899908995897     Document Type: Short Survey

References (24)

1. Dolin R. Influenza. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 14th edn. New York: McGraw-Hill; 1998: 1112-6.
2. Nicholson KG. Clinical features of influenza. Sem Respir Infect 1992; 7: 26-37.
3. Cate TR. Clinical manifestations and consequences of influenza. Am J Med 1987; 82: 15-9.
4. Schoenbaum SC. Economic impact of influenza. The individual's perspective. Am J Med 1987; 82: 26-30.
5. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987; 32: 20-5.
6. Hampson AW. Surveillance for pandemic influenza. J Infect Dis 1997; 176 Suppl 1: S8-13.
7. Wiselka M. Influenza; diagnosis, management, and prophylaxis. BMJ 1994; 309: 126.
8. White D. Influenza vaccination: is it worth it? Aust Fam Physician 1991; 20: 543-5, 548-52.
9. Van Voris LP, Newell PM. Antivirals for the chemoprophylaxis and treatment of influenza. Sem Respir Infect 1992; 7: 61-70.
10. Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997; 176 Suppl 1: S32-7.
11. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Curr Opin Infect Dis 1994; 7: 674-7.
12. Belshe RB, Burk B, Newman F, Cerruti RL, Sims IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430-5.
13. Treanor J. Viral infections of the respiratory tract: prevention and treatment. Int J Antimicrob Agents 1994; 4: 1-22.
14. Luo M, Air GM, Brouillette WJ. Design of aromatic inhibitors of influenza virus neuraminidase. J Infect Dis 1997; 176 Suppl 1: S62-5.
15. Von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. Regional design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23.
16. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275: 295-9.
17. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80.
18. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
19. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [published erratum appears in Lancet 1999; 353: 504 and 1104]. Lancet 1998; 352: 1877-81.
20. Alezari J, Klein T, Stapleton J, Elliott M, Flack N, Keene O. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and 'high risk' individuals in North America. Abstracts of the 21st International Congress of Chemotherapy; 1999 July 4-7; Birmingham, UK. International Society of Chemotherapy.
21. Fleming D, Makela M, Pauksens K, Man C, Webster A, Keene O. 'High risk' and otherwise healthy patients demonstrate alleviation of influenza symptoms 2.5 days earlier following inhaled zanamivir treatment; European study, winter 1997/98. Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America (IDSA); 1998 Nov 12-15; Denver, CO. Washington, DC: Infectious Diseases Society of America.
22. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, et al. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialadase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9.
23. Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG. Successful treatment of naturally occurring influenza A/ USSR/77 HINI. JAMA 1981; 245: 1128-31.
24. Cass LMR, Efthymiopoulos C, Marsh J, Bye A. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet 1999; 36 Supp 1: 13-9.